Analysis of linear accelerator-based fractionated stereotactic radiotherapy in brain metastases: efficacy, safety, and dose tolerances
LINAC-FSRT is safe and effective in BM. BED10>55 Gy notably enhances OS post-LINAC-FSRT and may benefit LC. High BED10 FSRT with targeted therapy likely boosts synergy, and concurrent targeted therapy significantly improves iPFS. Diminishing dose volume constraints at different fractions based on the HyTEC guidelines is feasible.
Authors
- Naixin Ding
- Liping Deng (ORCID: https://orcid.org/0000-0002-4897-7721)
- Yuhong Li (ORCID: https://orcid.org/0000-0003-1684-207X)
- Wei Chen (ORCID: https://orcid.org/0000-0003-0634-8326)
- Tingting Wang (ORCID: https://orcid.org/0000-0002-3809-2209)
- Xiaomin Lu (ORCID: https://orcid.org/0000-0001-6798-2668)
- Huiying Ma (ORCID: https://orcid.org/0009-0005-2748-8493)
- Rui Hua
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- Jiangsu Cancer Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-21
- DOI
- https://doi.org/10.3389/fonc.2024.1471004
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China